Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial - Trial NCT06308939
Access comprehensive clinical trial information for NCT06308939 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 81 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang Cancer Hospital
Timeline & Enrollment
Phase 2
Mar 08, 2024
Aug 31, 2026
Primary Outcome
Objective Response Rate (ORR)
Summary
This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety
 of Eribulin combined with Sintilimab in the first-line treatment of unresectable locally
 advanced or metastatic HER2-negative breast cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06308939
Non-Device Trial